Tranzactioneaza Allena Pharmaceuticals, (US.ALNA) - 0.0734 USD (%) Tranzactioneaza
Indici
Descriere companie
Allena Pharmaceuticals, Inc.(www.allenapharma.com) is a late-stage, clinical biopharmaceutical company. The Company is engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD.